Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (3323)	7/2/2021 12:47:41 PM
From: Biotechwantabe	Read Replies (2) \| Respond to of 3557

Should be good target for Alnylam. Once every 6m jab to control weight.

To: Felix B who wrote (3323)	7/3/2021 10:57:43 PM
From: CuttingEdge Bio	Respond to of 3557

I used to think, wow, they discovered this target and partnered with Alnylam before even announcing it, and some other company got something into the clinic with a drug before them, what a f*ck up! But actually now after watching the Guggenheim presentation, I start to think maybe it's Arrowhead that doesn't know what it's in for. REGN may have an edge on trial design for this and for other outcomes trial settings thanks to RGC. Seems like market is finally waking up to what REGN has cooking.